Caenorhabditis elegans: A model to investigate oxidative stress and metal dyshomeostasis in Parkinson's disease

Frontiers in Aging Neuroscience

Volumn 6, Issue MAY, 2014, Pages

  Chege, Patricia M ^a   McColl, Gawain ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Axonal transport; C. elegans; Metals; Microtubules; Oxidative stress; Parkinson's disease; tau; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; COBALT; COPPER; IRON; MAGNESIUM; MANGANESE; NICKEL; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; ZINC;

APOPTOSIS; BRAIN REGION; CAENORHABDITIS ELEGANS; COGNITIVE DEFECT; DEPRESSION; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; INSOMNIA; IRON METABOLISM; METAL ION DYSHOMEOSTASIS; METAL METABOLISM; NERVE CELL NETWORK; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PSYCHOSIS; REVIEW; RNA INTERFERENCE; SYNAPTIC TRANSMISSION; SYSTEMATIC REVIEW (TOPIC);

EID: 84901314467     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00089     Document Type: Review

References (210)

1. Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W. H., Castillo, P. E., et al. (2000). Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252. doi: 10.1016/S0896-6273(00)80886-7
2. Alam, Z. I., Daniel, S. E., Lees, A. J., Marsden, D. C., Jenner, P., and Halliwell, B. (1997a). A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69, 1326-1329. doi: 10.1046/j.1471-4159.1997.69031326.x
3. Alam, Z. I., Jenner, A., Daniel, S. E., Lees, A. J., Cairns, N., Marsden, C. D., et al. (1997b). Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69, 1196-1203. doi: 10.1046/j.1471-4159.1997.69031196.x
4. Alim, M. A., Hossain, M. S., Arima, K., Takeda, K., Izumiyama, Y., Nakamura, M., et al. (2002). Tubulin seeds alpha-synuclein fibril formation. J. Biol. Chem. 277, 2112-2117. doi: 10.1074/jbc.M102981200
5. Alim, M. A., Ma, Q.-L., Takeda, K., Aizawa, T., Matsubara, M., Nakamura, M., et al. (2004). Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein. J. Alzheimers Dis. 6, 435-442
6. Andreini, C., Bertini, I., Cavallaro, G., Holliday, G. L., and Thornton, J. M. (2008). Metal ions in biological catalysis: from enzyme databases to general principles. J. Biol. Inorg. Chem. 13, 1205-1218. doi: 10.1007/s00775-008-0404-5
7. Appel-Cresswell, S., Vilarino-Guell, C., Encarnacion, M., Sherman, H., Yu, I., Shah, B., et al. (2013). Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord. 28, 811-813. doi: 10.1002/mds.25421
8. Arima, K., Hirai, S., Sunohara, N., Aoto, K., Izumiyama, Y., Ueda, K., et al. (1999). Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain Res. 843, 53-61. doi: 10.1016/S0006-8993(99)01848-X
9. Arredondo, M., and Nunez, M. T. (2005). Iron and copper metabolism. Mol. Aspects Med. 26, 313-327. doi: 10.1016/j.mam.2005.07.010
10. Bains, J. S., and Shaw, C. A. (1997). Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res. Brain Res. Rev. 25, 335-358. doi: 10.1016/S0165-0173(97)00045-3
11. Bancher, C., Braak, H., Fischer, P., and Jellinger, K. A. (1993). Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci. Lett. 162, 179-182. doi: 10.1016/0304-3940(93)90590-H
12. Bargmann, C. I. (1998). Neurobiology of the Caenorhabditis elegans genome. Science 282, 2028-2033. doi: 10.1126/science.282.5396.2028
13. Ben-Shachar, D., and Youdim, M. B. (1991). Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J. Neurochem. 57, 2133-2135. doi: 10.1111/j.1471-4159.1991.tb06432.x
14. Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., et al. (2003). Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256-259. doi: 10.1126/science.1077209
15. Braak, H., Del Tredici, K., Rub, U., De Vos, R. A., Jansen Steur, E. N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211. doi: 10.1016/S0197-4580(02)00065-9
16. Brandt, R., Gergou, A., Wacker, I., Fath, T., and Hutter, H. (2009). A Caenorhabditis elegans model of tau hyperphosphorylation: induction of developmental defects by transgenic overexpression of Alzheimer's disease-like modified tau. Neurobiol. Aging 30, 22-33. doi: 10.1016/j.neurobiolaging.2007.05.011
17. Bras, J., Simon-Sanchez, J., Federoff, M., Morgadinho, A., Januario, C., Ribeiro, M., et al. (2009). Lack of replication of association between GIGYF2 variants and Parkinson disease. Hum. Mol. Genet. 18, 341-346. doi: 10.1093/hmg/ddn340
18. Braungart, E., Gerlach, M., Riederer, P., Baumeister, R., and Hoener, M. C. (2004). Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings. Neurodegener. Dis. 1, 175-183. doi: 10.1159/000080983
19. Brenner, S. (1974). The genetics of Caenorhabditis elegans. Genetics 77, 71-94.
20. Buter, T. C., van den Hout, A., Matthews, F. E., Larsen, J. P., Brayne, C., and Aarsland, D. (2008). Dementia and survival in Parkinson disease: a 12-year population study. Neurology 70, 1017-1022. doi: 10.1212/01.wnl.0000306632.43729.24
21. Cairo, G., Recalcati, S., Pietrangelo, A., and Minotti, G. (2002). The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage. Free Radic. Biol. Med. 32, 1237-1243. doi: 10.1016/S0891-5849(02)00825-0
22. Camakaris, J., Voskoboinik, I., and Mercer, J. F. (1999). Molecular mechanisms of copper homeostasis. Biochem. Biophys. Res. Commun. 261, 225-232. doi: 10.1006/bbrc.1999.1073
23. Cao, S., Gelwix, C. C., Caldwell, K. A., and Caldwell, G. A. (2005). Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J. Neurosci. 25, 3801-3812. doi: 10.1523/JNEUROSCI.5157-04.2005
24. Cappelletti, G., Surrey, T., and Maci, R. (2005). The parkinsonism producing neurotoxin MPP+ affects microtubule dynamics by acting as a destabilising factor. FEBS Lett. 579, 4781-4786. doi: 10.1016/j.febslet.2005.07.058
25. Cartelli, D., Casagrande, F., Busceti, C. L., Bucci, D., Molinaro, G., Traficante, A., et al. (2013). Microtubule alterations occur early in experimental parkinsonism and the microtubule stabilizer epothilone D is neuroprotective. Sci. Rep. 3:1837. doi: 10.1038/srep01837
26. Catoire, H., Dion, P. A., Xiong, L., Amari, M., Gaudet, R., Girard, S. L., et al. (2011). Restless legs syndrome-associated MEIS1 risk variant influences iron homeostasis. Ann. Neurol. 70, 170-175. doi: 10.1002/ana.22435
27. Chalfie, M., Tu, Y., Euskirchen, G., Ward, W. W., and Prasher, D. C. (1994). Green fluorescent protein as a marker for gene expression. Science 263, 802-805. doi: 10.1126/science.8303295
28. Chartier-Harlin, M. C., Dachsel, J. C., Vilarino-Guell, C., Lincoln, S. J., Lepretre, F., Hulihan, M. M., et al. (2011). Translation initiator EIF4G1 mutations in familial Parkinson disease. Am. J. Hum. Genet. 89, 398-406. doi: 10.1016/j.ajhg.2011.08.009
29. Chew, Y. L., Fan, X., Gotz, J., and Nicholas, H. R. (2013). PTL-1 regulates neuronal integrity and lifespan in C. elegans. J. Cell Sci. 126, 2079-2091. doi: 10.1242/jcs.jcs124404
30. Cobbold, C., Coventry, J., Ponnambalam, S., and Monaco, A. P. (2004). Actin and microtubule regulation of trans-Golgi network architecture, and copper-dependent protein transport to the cell surface. Mol. Membr. Biol. 21, 59-66. doi: 10.1080/096870310001607350
31. Connor, J. R., Snyder, B. S., Arosio, P., Loeffler, D. A., and Lewitt, P. (1995). A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J. Neurochem. 65, 717-724. doi: 10.1046/j.1471-4159.1995.65020717.x
32. Consortium, C. E. S. (1998). Genome sequence of the nematode C. elegans: a platform for investigating biology. Science 282, 2012-2018. doi: 10.1126/science.282.5396.2012
33. Cooper, A. A., Gitler, A. D., Cashikar, A., Haynes, C. M., Hill, K. J., Bhullar, B., et al. (2006). Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313, 324-328. doi: 10.1126/science.1129462
34. Crouch, P. J., Savva, M. S., Hung, L. W., Donnelly, P. S., Mot, A. I., Parker, S. J., et al. (2011). The Alzheimer's therapeutic PBT2 promotes amyloid-beta degradation and GSK3 phosphorylation via a metal chaperone activity. J. Neurochem. 119, 220-230. doi: 10.1111/j.1471-4159.2011.07402.x
35. Culetto, E., and Sattelle, D. B. (2000). A role for Caenorhabditis elegans in understanding the function and interactions of human disease genes. Hum. Mol. Genet. 9, 869-877. doi: 10.1093/hmg/9.6.869
36. Curtis, A. R., Fey, C., Morris, C. M., Bindoff, L. A., Ince, P. G., Chinnery, P. F., et al. (2001). Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 28, 350-354. doi: 10.1038/ng571
37. Dexter, D. T., Carayon, A., Javoy-Agid, F., Agid, Y., Wells, F. R., Daniel, S. E., et al. (1991). Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114(pt 4), 1953-1975. doi: 10.1093/brain/114.4.1953
38. Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., Lees, A., et al. (1989a). Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52, 381-389. doi: 10.1111/j.1471-4159.1989.tb09133.x
39. Dexter, D. T., Holley, A. E., Flitter, W. D., Slater, T. F., Wells, F. R., Daniel, S. E., et al. (1994). Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 9, 92-97. doi: 10.1002/mds.870090115
40. Dexter, D. T., Wells, F. R., Lees, A. J., Agid, F., Agid, Y., Jenner, P., et al. (1989b). Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52, 1830-1836. doi: 10.1111/j.1471-4159.1989.tb07264.x
41. Dixit, R., Ross, J. L., Goldman, Y. E., and Holzbaur, E. L. F. (2008). Differential regulation of dynein and kinesin motor proteins by tau. Science 319, 1086-1089. doi: 10.1126/science.1152993
42. Dorman, J. B., Albinder, B., Shroyer, T., and Kenyon, C. (1995). The age-1 and daf-2 genes function in a common pathway to control the lifespan of Caenorhabditis elegans. Genetics 141, 1399-1406.
43. Duka, T., Duka, V., Joyce, J. N., and Sidhu, A. (2009). Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J. 23, 2820-2830. doi: 10.1096/fj.08-120410
44. Ebneth, A., Godemann, R., Stamer, K., Illenberger, S., Trinczek, B., and Mandelkow, E. (1998). Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J. Cell Biol. 143, 777-794. doi: 10.1083/jcb.143.3.777
45. Edvardson, S., Cinnamon, Y., Ta-Shma, A., Shaag, A., Yim, Y. I., Zenvirt, S., et al. (2012). A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. PLoS ONE 7:e36458. doi: 10.1371/journal.pone.0036458
46. Edwards, T. L., Scott, W. K., Almonte, C., Burt, A., Powell, E. H., Beecham, G. W., et al. (2010). Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann. Hum. Genet. 74, 97-109. doi: 10.1111/j.1469-1809.2009.00560.x
47. Ellis, H. M., and Horvitz, H. R. (1986). Genetic control of programmed cell death in the nematode C. elegans. Cell 44, 817-829. doi: 10.1016/0092-8674(86)90004-8
48. Faber, P. W., Alter, J. R., Macdonald, M. E., and Hart, A. C. (1999). Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc. Natl. Acad. Sci. U.S.A. 96, 179-184. doi: 10.1073/pnas.96.1.179
49. Fang, F. C. (2004). Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat. Rev. Microbiol. 2, 820-832. doi: 10.1038/nrmicro1004
50. Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., and Mello, C. C. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811. doi: 10.1038/35888
51. Forno, L. S. (1996). Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55, 259-272. doi: 10.1097/00005072-199603000-00001
52. Freeman, L. R., and Keller, J. N. (2012). Oxidative stress and cerebral endothelial cells: regulation of the blood-brain-barrier and antioxidant based interventions. Biochim. Biophys. Acta 1822, 822-829. doi: 10.1016/j.bbadis.2011.12.009
53. Friedman, D. B., and Johnson, T. E. (1988). A mutation in the age-1 gene in Caenorhabditis elegans lengthens life and reduces hermaphrodite fertility. Genetics 118, 75-86.
54. Fuxe, K., and Jonsson, G. (1973). The histochemical fluorescence method for the demonstration of catecholamines. Theory, practice and application. J. Histochem. Cytochem. 21, 293-311. doi: 10.1177/21.4.293
55. Geddes, J. W. (2005). alpha-Synuclein: a potent inducer of tau pathology. Exp. Neurol. 192, 244-250. doi: 10.1016/j.expneurol.2004.12.002
56. Gerlach, M., Ben-Shachar, D., Riederer, P., and Youdim, M. B. (1994). Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63, 793-807. doi: 10.1046/j.1471-4159.1994.63030793.x
57. Giasson, B. I., Forman, M. S., Higuchi, M., Golbe, L. I., Graves, C. L., Kotzbauer, P. T., et al. (2003). Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300, 636-640. doi: 10.1126/science.1082324
58. Gkouvatsos, K., Papanikolaou, G., and Pantopoulos, K. (2012). Regulation of iron transport and the role of transferrin. Biochim. Biophys. Acta 1820, 188-202. doi: 10.1016/j.bbagen.2011.10.013
59. Goedert, C., Baur, C. P., Ahringer, J., Jakes, R., Hasegawa, M., Spillantini, M. G., et al. (1996). PTL-1, a microtubule-associated protein with tau-like repeats from the nematode Caenorhabditis elegans. J. Cell Sci. 109, 2661-2672.
60. Good, P. F., Olanow, C. W., and Perl, D. P. (1992). Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res. 593, 343-346. doi: 10.1016/0006-8993(92)91334-B
61. Gordon, P., Hingula, L., Krasny, M. L., Swienckowski, J. L., Pokrywka, N. J., and Raley-Susman, K. M. (2008). The invertebrate microtubule-associated protein PTL-1 functions in mechanosensation and development in Caenorhabditis elegans. Dev. Genes Evol. 218, 541-551. doi: 10.1007/s00427-008-0250-z
62. Gotz, M. E., Double, K., Gerlach, M., Youdim, M. B., and Riederer, P. (2004). The relevance of iron in the pathogenesis of Parkinson's disease. Ann. N.Y. Acad. Sci. 1012, 193-208. doi: 10.1196/annals.1306.017
63. Haacke, E. M., Ayaz, M., Khan, A., Manova, E. S., Krishnamurthy, B., Gollapalli, L., et al. (2007). Establishing a baseline phase behavior in magnetic resonance imaging to determine normal vs. abnormal iron content in the brain. J. Magn. Reson. Imaging 26, 256-264. doi: 10.1002/jmri.22987
64. Halliwell, B. (2001). Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18, 685-716. doi: 10.2165/00002512-200118090-00004
65. Halliwell, B., and Gutteridge, J. M. (1986). Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch. Biochem. Biophys. 246, 501-514. doi: 10.1016/0003-9861(86)90305-X
66. Hamamichi, S., Rivas, R. N., Knight, A. L., Cao, S., Caldwell, K. A., and Caldwell, G. A. (2008). Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model. Proc. Natl. Acad. Sci. U.S.A. 105, 728-733. doi: 10.1073/pnas.0711018105
67. Harris, Z. L., Klomp, L. W., and Gitlin, J. D. (1998). Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am. J. Clin. Nutr. 67, 972S-977S.
68. Hashimoto, M., Hsu, L. J., Xia, Y., Takeda, A., Sisk, A., Sundsmo, M., et al. (1999). Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10, 717-721. doi: 10.1097/00001756-199903170-00011
69. Healy, D. G., Abou-Sleiman, P. M., Casas, J. P., Ahmadi, K. R., Lynch, T., Gandhi, S., et al. (2006). UCHL-1 is not a Parkinson's disease susceptibility gene. Ann. Neurol. 59, 627-633. doi: 10.1002/ana.20757
70. Hedgecock, E. M., Sulston, J. E., and Thomson, J. N. (1983). Mutations affecting programmed cell deaths in the nematode Caenorhabditis elegans. Science 220, 1277-1279. doi: 10.1126/science.6857247
71. Hekimi, S., Lapointe, J., and Wen, Y. (2011). Taking a "good" look at free radicals in the aging process. Trends Cell Biol. 21, 569-576. doi: 10.1016/j.tcb.2011.06.008
72. Hely, M. A., Reid, W. G., Adena, M. A., Halliday, G. M., and Morris, J. G. (2008). The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23, 837-844. doi: 10.1002/mds.21956
73. Hills, T., Brockie, P. J., and Maricq, A. V. (2004). Dopamine and glutamate control area-restricted search behavior in Caenorhabditis elegans. J. Neurosci. 24, 1217-1225. doi: 10.1523/JNEUROSCI.1569-03.2004
74. Hirtz, D., Thurman, D. J., Gwinn-Hardy, K., Mohamed, M., Chaudhuri, A. R., and Zalutsky, R. (2007). How common are the "common" neurologic disorders? Neurology 68, 326-337. doi: 10.1212/01.wnl.0000252807.38124.a3
75. Hornykiewicz, O., and Kish, S. J. (1987). Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45, 19-34.
76. Hwang, O. (2013). Role of oxidative stress in Parkinson's disease. Exp. Neurobiol. 22, 11-17. doi: 10.5607/en.2013.22.1.11
77. Irizarry, M. C., Growdon, W., Gomez-Isla, T., Newell, K., George, J. M., Clayton, D. F., et al. (1998). Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J. Neuropathol. Exp. Neurol. 57, 334-337. doi: 10.1097/00005072-199804000-00005
78. Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., De Silva, H. A., et al. (1995). The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467-475. doi: 10.1016/0896-6273(95)90302-X
79. Jancsik, V., Filliol, D., and Rendon, A. (1996). Tau proteins bind to kinesin and modulate its activation by microtubules. Neurobiology (Bp) 4, 417-429.
80. Janvin, C. C., Larsen, J. P., Aarsland, D., and Hugdahl, K. (2006). Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov. Disord. 21, 1343-1349. doi: 10.1002/mds.20974
81. Jenner, P. (2003). Oxidative stress in Parkinson's disease. Ann. Neurol. 53(Suppl. 3), S26-S36. discussion: S36-S38. doi: 10.1002/ana.10483
82. Jenner, P., and Olanow, C. W. (1996). Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47, 161S-170S. doi: 10.1212/WNL.47.6_Suppl_3.161S
83. Jensen, P. H., Hager, H., Nielsen, M. S., Hojrup, P., Gliemann, J., and Jakes, R. (1999). alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J. Biol. Chem. 274, 25481-25489. doi: 10.1074/jbc.274.36.25481
84. Jiang, D., Shi, S., Zhang, L., Liu, L., Ding, B., Zhao, B., et al. (2013). Inhibition of the Fe(III)-catalyzed dopamine oxidation by ATP and its relevance to oxidative stress in Parkinson's disease. ACS Chem. Neurosci. 4, 1305-1313. doi: 10.1021/cn400105d
85. Joachim, C. L., Morris, J. H., Kosik, K. S., and Selkoe, D. J. (1987). Tau antisera recognize neurofibrillary tangles in a range of neurodegenerative disorders. Ann. Neurol. 22, 514-520. doi: 10.1002/ana.410220411
86. Jomova, K., Vondrakova, D., Lawson, M., and Valko, M. (2010). Metals, oxidative stress and neurodegenerative disorders. Mol. Cell. Biochem. 345, 91-104. doi: 10.1007/s11010-010-0563-x
87. Junn, E., Taniguchi, H., Jeong, B. S., Zhao, X., Ichijo, H., and Mouradian, M. M. (2005). Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc. Natl. Acad. Sci. U.S.A. 102, 9691-9696. doi: 10.1073/pnas.0409635102
88. Kamp, F., Exner, N., Lutz, A. K., Wender, N., Hegermann, J., Brunner, B., et al. (2010). Inhibition of mitochondrial fusion by alpha-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J. 29, 3571-3589. doi: 10.1038/emboj.2010.223
89. Kanaan, N. M., Morfini, G., Pigino, G., Lapointe, N. E., Andreadis, A., Song, Y., et al. (2012). Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport. Neurobiol. Aging 33, 826.e15-826.e30. doi: 10.1016/j.neurobiolaging.2011.06.006
90. Karpinar, D. P., Balija, M. B., Kugler, S., Opazo, F., Rezaei-Ghaleh, N., Wender, N., et al. (2009). Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J. 28, 3256-3268. doi: 10.1038/emboj.2009.257
91. Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., et al. (2003). Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37, 899-909. doi: 10.1016/S0896-6273(03)00126-0
92. Kenyon, C., Chang, J., Gensch, E., Rudner, A., and Tabtiang, R. (1993). A C. elegans mutant that lives twice as long as wild type. Nature 366, 461-464. doi: 10.1038/366461a0
93. Kepp, K. P. (2012). Bioinorganic chemistry of Alzheimer's disease. Chem. Rev. 112, 5193-5239. doi: 10.1021/cr300009x
94. Kidd, M. (1963). Paired helical filaments in electron microscopy of Alzheimer's disease. Nature 197, 192-193. doi: 10.1038/197192b0
95. Kimura, K. D., Tissenbaum, H. A., Liu, Y., and Ruvkun, G. (1997). daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science 277, 942-946. doi: 10.1126/science.277.5328.942
96. Kish, S. J., Shannak, K., and Hornykiewicz, O. (1988). Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 318, 876-880. doi: 10.1056/NEJM198804073181402
97. Kokhan, V. S., Afanasyeva, M. A., and Van'kin, G. I. (2012). alpha-Synuclein knockout mice have cognitive impairments. Behav. Brain Res. 231, 226-230. doi: 10.1016/j.bbr.2012.03.026
98. Koroglu, C., Baysal, L., Cetinkaya, M., Karasoy, H., and Tolun, A. (2013). DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability. Parkinsonism Relat. Disord. 19, 320-324. doi: 10.1016/j.parkreldis.2012.11.006
99. Kosik, K. S., and Finch, E. A. (1987). MAP2 and tau segregate into dendritic and axonal domains after the elaboration of morphologically distinct neurites: an immunocytochemical study of cultured rat cerebrum. J. Neurosci. 7, 3142-3153.
100. Kraemer, B. C., Zhang, B., Leverenz, J. B., Thomas, J. H., Trojanowski, J. Q., and Schellenberg, G. D. (2003). Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc. Natl. Acad. Sci. U.S.A. 100, 9980-9985. doi: 10.1073/pnas.1533448100
101. Krebs, C. E., Karkheiran, S., Powell, J. C., Cao, M., Makarov, V., Darvish, H., et al. (2013). The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive Parkinsonism with generalized seizures. Hum. Mutat. 34, 1200-1207. doi: 10.1002/humu.22372
102. Kristinsson, J., Snaedal, J., Torsdottir, G., and Johannesson, T. (2012). Ceruloplasmin and iron in Alzheimer's disease and Parkinson's disease: a synopsis of recent studies. Neuropsychiatr. Dis. Treat. 8, 515-521. doi: 10.2147/NDT.S34729
103. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., et al. (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108. doi: 10.1038/ng0298-106
104. Kuwahara, T., Koyama, A., Gengyo-Ando, K., Masuda, M., Kowa, H., Tsunoda, M., et al. (2006). Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans. J. Biol. Chem. 281, 334-340. doi: 10.1074/jbc.M504860200
105. Kuwahara, T., Koyama, A., Koyama, S., Yoshina, S., Ren, C. H., Kato, T., et al. (2008). A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in alpha-synuclein transgenic C. elegans. Hum. Mol. Genet. 17, 2997-3009. doi: 10.1093/hmg/ddn198
106. Lai, C. H., Chou, C. Y., Ch'ang, L. Y., Liu, C. S., and Lin, W. (2000). Identification of novel human genes evolutionarily conserved in Caenorhabditis elegans by comparative proteomics. Genome Res. 10, 703-713. doi: 10.1101/gr.10.5.703
107. Lakso, M., Vartiainen, S., Moilanen, A. M., Sirvio, J., Thomas, J. H., Nass, R., et al. (2003). Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J. Neurochem. 86, 165-172. doi: 10.1046/j.1471-4159.2003.01809.x
108. Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., et al. (2008). Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 7, 779-786. doi: 10.1016/S1474-4422(08)70167-4
109. Lapointe, N. E., Morfini, G., Pigino, G., Gaisina, I. N., Kozikowski, A. P., Binder, L. I., et al. (2009). The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J. Neurosci. Res. 87, 440-451. doi: 10.1002/jnr.21850
110. Lee, D. W., and Andersen, J. K. (2010). Iron elevations in the aging Parkinsonian brain: a consequence of impaired iron homeostasis? J. Neurochem. 112, 332-339. doi: 10.1111/j.1471-4159.2009.06470.x
111. Lee, F. J., Liu, F., Pristupa, Z. B., and Niznik, H. B. (2001). Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15, 916-926. doi: 10.1096/fj.00-0334com
112. Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K., et al. (2012). Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat. Med. 18, 291-295. doi: 10.1038/nm.2613
113. Li, W. W., Yang, R., Guo, J. C., Ren, H. M., Zha, X. L., Cheng, J. S., et al. (2007). Localization of alpha-synuclein to mitochondria within midbrain of mice. Neuroreport 18, 1543-1546. doi: 10.1097/WNR.0b013e3282f03db4
114. Liochev, S. I., and Fridovich, I. (1994). The role of O2.- in the production of HO.: in vitro and in vivo. Free Radic. Biol. Med. 16, 29-33. doi: 10.1016/0891-5849(94)90239-9
115. Lotharius, J., and O'Malley, K. L. (2000). The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem. 275, 38581-38588. doi: 10.1074/jbc.M005385200
116. Luo, Y., Umegaki, H., Wang, X., Abe, R., and Roth, G. S. (1998). Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J. Biol. Chem. 273, 3756-3764. doi: 10.1074/jbc.273.6.3756
117. Magnani, E., Fan, J., Gasparini, L., Golding, M., Williams, M., Schiavo, G., et al. (2007). Interaction of tau protein with the dynactin complex. EMBO J. 26, 4546-4554. doi: 10.1038/sj.emboj.7601878
118. Mandelkow, E. M., Stamer, K., Vogel, R., Thies, E., and Mandelkow, E. (2003). Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol. Aging 24, 1079-1085. doi: 10.1016/j.neurobiolaging.2003.04.007
119. Marttila, R. J., Lorentz, H., and Rinne, U. K. (1988). Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J. Neurol. Sci. 86, 321-331. doi: 10.1016/0022-510X(88)90108-6
120. McColl, G., Roberts, B. R., Gunn, A. P., Perez, K. A., Tew, D. J., Masters, C. L., et al. (2009). The Caenorhabditis elegans A beta 1-42 model of Alzheimer disease predominantly expresses A beta 3-42. J. Biol. Chem. 284, 22697-22702. doi: 10.1074/jbc.C109.028514
121. McColl, G., Roberts, B. R., Pukala, T. L., Kenche, V. B., Roberts, C. M., Link, C. D., et al. (2012). Utility of an improved model of amyloid-beta (Abeta(1)(-)(4)(2)) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease. Mol. Neurodegener. 7, 57. doi: 10.1186/1750-1326-7-57
122. McCormick, A. V., Wheeler, J. M., Guthrie, C. R., Liachko, N. F., and Kraemer, B. C. (2013). Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity. Biol. Psychiatry 73, 464-471. doi: 10.1016/j.biopsych.2012.08.027
123. McDonald, P. W., Jessen, T., Field, J. R., and Blakely, R. D. (2006). Dopamine signaling architecture in Caenorhabditis elegans. Cell. Mol. Neurobiol. 26, 593-618. doi: 10.1007/s10571-006-9003-6
124. Moos, T., and Rosengren Nielsen, T. (2006). Ferroportin in the postnatal rat brain: implications for axonal transport and neuronal export of iron. Semin. Pediatr. Neurol. 13, 149-157. doi: 10.1016/j.spen.2006.08.003
125. Morfini, G., Pigino, G., Opalach, K., Serulle, Y., Moreira, J. E., Sugimori, M., et al. (2007). 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C. Proc. Natl. Acad. Sci. U.S.A. 104, 2442-2447. doi: 10.1073/pnas.0611231104
126. Muntane, G., Dalfo, E., Martinez, A., and Ferrer, I. (2008). Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. Neuroscience 152, 913-923. doi: 10.1016/j.neuroscience.2008.01.030
127. Murakami, S., and Johnson, T. E. (1996). A genetic pathway conferring life extension and resistance to UV stress in Caenorhabditis elegans. Genetics 143, 1207-1218.
128. Nagatsu, T. (1995). Tyrosine hydroxylase: human isoforms, structure and regulation in physiology and pathology. Essays Biochem. 30, 15-35.
129. Nakajo, S., Shioda, S., Nakai, Y., and Nakaya, K. (1994). Localization of phosphoneuroprotein 14 (PNP 14) and its mRNA expression in rat brain determined by immunocytochemistry and in situ hybridization. Brain Res. Mol. Brain Res. 27, 81-86. doi: 10.1016/0169-328X(94)90187-2
130. Nass, R., Hall, D. H., Miller, D. M. and Blakely, R. D. (2002). Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U.S.A. 99, 3264-3269. doi: 10.1073/pnas.042497999
131. Nemani, V. M., Lu, W., Berge, V., Nakamura, K., Onoa, B., Lee, M. K., et al. (2010). Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65, 66-79. doi: 10.1016/j.neuron.2009.12.023
132. Niki, E. (2009). Lipid peroxidation: physiological levels and dual biological effects. Free Radic. Biol. Med. 47, 469-484. doi: 10.1016/j.freeradbiomed.2009.05.032
133. Nunez, M. T., Urrutia, P., Mena, N., Aguirre, P., Tapia, V., and Salazar, J. (2012). Iron toxicity in neurodegeneration. Biometals 25, 761-776. doi: 10.1007/s10534-012-9523-0
134. Oakley, A. E., Collingwood, J. F., Dobson, J., Love, G., Perrott, H. R., Edwardson, J. A., et al. (2007). Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 68, 1820-1825. doi: 10.1212/01.wnl.0000262033.01945.9a
135. Offen, D., Hochman, A., Gorodin, S., Ziv, I., Shirvan, A., Barzilai, A., et al. (1999). Oxidative stress and neuroprotection in Parkinson's disease: implications from studies on dopamine-induced apoptosis. Adv. Neurol. 80, 265-269.
136. Olanow, C. W., and Arendash, G. W. (1994). Metals and free radicals in neurodegeneration. Curr. Opin. Neurol. 7, 548-558. doi: 10.1097/00019052-199412000-00013
137. Orth, M., and Schapira, A. H. (2002). Mitochondrial involvement in Parkinson's disease. Neurochem. Int. 40, 533-541. doi: 10.1016/S0197-0186(01)00124-3
138. Pang, W. L., Kaur, A., Ratushny, A. V., Cvetkovic, A., Kumar, S., Pan, M., et al. (2013). Metallochaperones regulate intracellular copper levels. PLoS Comput. Biol. 9:e1002880. doi: 10.1371/journal.pcbi.1002880
139. Pankratz, N., Nichols, W. C., Uniacke, S. K., Halter, C., Rudolph, A., Shults, C., et al. (2002). Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am. J. Hum. Genet. 71, 124-135. doi: 10.1086/341282
140. Pattison, D. I., Dean, R. T., and Davies, M. J. (2002). Oxidation of DNA, proteins and lipids by DOPA, protein-bound DOPA, and related catechol(amine)s. Toxicology 177, 23-37. doi: 10.1016/S0300-483X(02)00193-2
141. Pezzella, A., D'Ischia, M., Napolitano, A., Misuraca, G., and Prota, G. (1997). Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: a possible contributory mechanism for neuronal degeneration in Parkinson's disease. J. Med. Chem. 40, 2211-2216. doi: 10.1021/jm970099t
142. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047. doi: 10.1126/science.276.5321.2045
143. Ponting, C. P. (2001). Domain homologues of dopamine beta-hydroxylase and ferric reductase: roles for iron metabolism in neurodegenerative disorders? Hum. Mol. Genet. 10, 1853-1858. doi: 10.1093/hmg/10.17.1853
144. Pridgeon, J. W., Olzmann, J. A., Chin, L. S., and Li, L. (2007). PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol. 5:e172. doi: 10.1371/journal.pbio.0050172
145. Proukakis, C., Dudzik, C. G., Brier, T., Mackay, D. S., Cooper, J. M., Millhauser, G. L., et al. (2013). A novel alpha-synuclein missense mutation in Parkinson disease. Neurology 80, 1062-1064. doi: 10.1212/WNL.0b013e31828727ba
146. Przedborski, S., Levivier, M., Jiang, H., Ferreira, M., Jackson-Lewis, V., Donaldson, D., et al. (1995). Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67, 631-647. doi: 10.1016/0306-4522(95)00066-R
147. Pu, P., and Le, W. (2008). Dopamine neuron degeneration induced by MPP+ is independent of CED-4 pathway in Caenorhabditis elegans. Cell Res. 18, 978-981. doi: 10.1038/cr.2008.279
148. Qin, Z., Hu, D., Han, S., Reaney, S. H., Di Monte, D. A., and Fink, A. L. (2007). Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J. Biol. Chem. 282, 5862-5870. doi: 10.1074/jbc.M608126200
149. Quadri, M., Fang, M., Picillo, M., Olgiati, S., Breedveld, G. J., Graafland, J., et al. (2013). Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism. Hum. Mutat. 34, 1208-1215. doi: 10.1002/humu.22373
150. Rae, T. D., Schmidt, P. J., Pufahl, R. A., Culotta, V. C., and O'Halloran, T. V. (1999). Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science 284, 805-808. doi: 10.1126/science.284.5415.805
151. Rand, J. B., and Nonet, M. L. (1997). "Synaptic transmission," in C. elegans II, 2nd Edn., eds D. L. Riddle, T. Blumenthal, B. J. Meyer, and J. R. Priess. (New York, NY: Cold Spring Harbor), 611-643.
152. Rangel, N. A., Lin, L., Rakariyatham, K., Bach, A., Trinh, K., Clement, M. H., et al. (2012). Unincorporated iron pool is linked to oxidative stress and iron levels in Caenorhabditis elegans. Biometals 25, 971-985. doi: 10.1007/s10534-012-9563-5
153. Recchia, A., Debetto, P., Negro, A., Guidolin, D., Skaper, S. D., and Giusti, P. (2004). Alpha-synuclein and Parkinson's disease. FASEB J. 18, 617-626. doi: 10.1096/fj.03-0338rev
154. Ren, Y., Liu, W., Jiang, H., Jiang, Q., and Feng, J. (2005). Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J. Biol. Chem. 280, 34105-34112. doi: 10.1074/jbc.M503483200
155. Riederer, P., Sofic, E., Rausch, W. D., Schmidt, B., Reynolds, G. P., Jellinger, K., et al. (1989). Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515-520. doi: 10.1111/j.1471-4159.1989.tb09150.x
156. Ruan, Q., Harrington, A. J., Caldwell, K. A., Caldwell, G. A., and Standaert, D. G. (2010). VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's disease. Neurobiol. Dis. 37, 330-338. doi: 10.1016/j.nbd.2009.10.011
157. Saggu, H., Cooksey, J., Dexter, D., Wells, F. R., Lees, A., Jenner, P., et al. (1989). A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J. Neurochem. 53, 692-697. doi: 10.1111/j.1471-4159.1989.tb11759.x
158. Saha, S., Guillily, M. D., Ferree, A., Lanceta, J., Chan, D., Ghosh, J., et al. (2009). LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J. Neurosci. 29, 9210-9218. doi: 10.1523/JNEUROSCI.2281-09.2009
159. Salazar, J., Mena, N., Hunot, S., Prigent, A., Alvarez-Fischer, D., Arredondo, M., et al. (2008). Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 105, 18578-18583. doi: 10.1073/pnas.0804373105
160. Samann, J., Hegermann, J., von Gromoff, E., Eimer, S., Baumeister, R., and Schmidt, E. (2009). Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J. Biol. Chem. 284, 16482-16491. doi: 10.1074/jbc.M808255200
161. Sanyal, S., Wintle, R. F., Kindt, K. S., Nuttley, W. M., Arvan, R., Fitzmaurice, P., et al. (2004). Dopamine modulates the plasticity of mechanosensory responses in Caenorhabditis elegans. EMBO J. 23, 473-482. doi: 10.1038/sj.emboj.7600057
162. Sauer, H., and Oertel, W. H. (1994). Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59, 401-415. doi: 10.1016/0306-4522(94)90605-X
163. Sawin, E. R., Ranganathan, R., and Horvitz, H. R. (2000). C. elegans locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway. Neuron 26, 619-631. doi: 10.1016/S0896-6273(00)81199-X
164. Schafer, W. R., and Kenyon, C. J. (1995). A calcium-channel homologue required for adaptation to dopamine and serotonin in Caenorhabditis elegans. Nature 375, 73-78. doi: 10.1038/375073a0
165. Schneider, J. A., Li, J. L., Li, Y., Wilson, R. S., Kordower, J. H., and Bennett, D. A. (2006). Substantia nigra tangles are related to gait impairment in older persons. Ann. Neurol. 59, 166-173. doi: 10.1002/ana.20723
166. Sengstock, G. J., Olanow, C. W., Menzies, R. A., Dunn, A. J., and Arendash, G. W. (1993). Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers. J. Neurosci. Res. 35, 67-82. doi: 10.1002/jnr.490350109
167. Settivari, R., Levora, J., and Nass, R. (2009). The divalent metal transporter homologues SMF-1/2 mediate dopamine neuron sensitivity in caenorhabditis elegans models of manganism and parkinson disease. J. Biol. Chem. 284, 35758-35768. doi: 10.1074/jbc.M109.051409
168. Settivari, R., VanDuyn, N., Levora, J., and Nass, R. (2013). The Nrf2/SKN-1-dependent glutathione S-transferase pi homologue GST-1 inhibits dopamine neuron degeneration in a Caenorhabditis elegans model of manganism. Neurotoxicology 38, 51-60. doi: 10.1016/j.neuro.2013.05.014
169. Shemesh, O. A., Erez, H., Ginzburg, I., and Spira, M. E. (2008). Tau-induced traffic jams reflect organelles accumulation at points of microtubule polar mismatching. Traffic 9, 458-471. doi: 10.1111/j.1600-0854.2007.00695.x
170. Sies, H. (1991). Oxidative stress: from basic research to clinical application. Am. J. Med. 91, 31S-38S. doi: 10.1016/0002-9343(91)90281-2
171. Simon-Sanchez, J., and Singleton, A. B. (2008). Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls. Hum. Mol. Genet. 17, 1988-1993. doi: 10.1093/hmg/ddn096
172. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., et al. (2003). alpha-Synuclein locus triplication causes Parkinson's disease. Science 302:841. doi: 10.1126/science.1090278
173. Smeyne, M., and Smeyne, R. J. (2013). Glutathione metabolism and Parkinson's disease. Free Radic. Biol. Med. 62, 13-25. doi: 10.1016/j.freeradbiomed.2013.05.001
174. Smith, Y., Wichmann, T., Factor, S. A., and Delong, M. R. (2012). Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology 37, 213-246. doi: 10.1038/npp.2011.212
175. Sofic, E., Lange, K. W., Jellinger, K., and Riederer, P. (1992). Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142, 128-130. doi: 10.1016/0304-3940(92)90355-B
176. Sofic, E., Paulus, W., Jellinger, K., Riederer, P., and Youdim, M. B. (1991). Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 56, 978-982. doi: 10.1111/j.1471-4159.1991.tb02017.x
177. Sohal, R. S., and Orr, W. C. (2012). The redox stress hypothesis of aging. Free Radic. Biol. Med. 52, 539-555. doi: 10.1016/j.freeradbiomed.2011.10.445
178. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature 388, 839-840. doi: 10.1038/42166
179. Stamer, K., Vogel, R., Thies, E., Mandelkow, E., and Mandelkow, E. M. (2002). Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol. 156, 1051-1063. doi: 10.1083/jcb.200108057
180. Strauss, K. M., Martins, L. M., Plun-Favreau, H., Marx, F. P., Kautzmann, S., Berg, D., et al. (2005). Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum. Mol. Genet. 14, 2099-2111. doi: 10.1093/hmg/ddi215
181. Su, L. J., Auluck, P. K., Outeiro, T. F., Yeger-Lotem, E., Kritzer, J. A., Tardiff, D. F., et al. (2010). Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis. Model. Mech. 3, 194-208. doi: 10.1242/dmm.004267
182. Sulston, J., Dew, M., and Brenner, S. (1975). Dopaminergic neurons in the nematode Caenorhabditis elegans. J. Comp. Neurol. 163, 215-226. doi: 10.1002/cne.901630207
183. Tan, E. K., Lin, C. H., Tai, C. H., Tan, L. C., Chen, M. L., Li, R., et al. (2009). Non-synonymous GIGYF2 variants in Parkinson's disease from two Asian populations. Hum. Genet. 126, 425-430. doi: 10.1007/s00439-009-0678-x
184. Tardiff, D. F., Tucci, M. L., Caldwell, K. A., Caldwell, G. A., and Lindquist, S. (2012). Different 8-hydroxyquinolines protect models of TDP-43 protein, alpha-synuclein, and polyglutamine proteotoxicity through distinct mechanisms. J. Biol. Chem. 287, 4107-4120. doi: 10.1074/jbc.M111.308668
185. Thomas, B., and Beal, M. F. (2007). Parkinson's disease. Hum. Mol. Genet. 16, R183-R194. doi: 10.1093/hmg/ddm159
186. Trinczek, B., Ebneth, A., Mandelkow, E. M., and Mandelkow, E. (1999). Tau regulates the attachment/detachment but not the speed of motors in microtubule-dependent transport of single vesicles and organelles. J. Cell Sci. 112(pt 14), 2355-2367.
187. Ueda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., et al. (1993). Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90, 11282-11286. doi: 10.1073/pnas.90.23.11282
188. Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M., Harvey, K., Gispert, S., et al. (2004). Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158-1160. doi: 10.1126/science.1096284
189. Valentini, S., Cabreiro, F., Ackerman, D., Alam, M. M., Kunze, M. B., Kay, C. W., et al. (2012). Manipulation of in vivo iron levels can alter resistance to oxidative stress without affecting ageing in the nematode C. elegans. Mech. Ageing Dev. 133, 282-290. doi: 10.1016/j.mad.2012.03.003
190. VanDuyn, N., Settivari, R., Levora, J., Zhou, S., Unrine, J., and Nass, R. (2013). The metal transporter SMF-3/DMT-1 mediates aluminum-induced dopamine neuron degeneration. J. Neurochem. 124, 147-157. doi: 10.1111/jnc.12072
191. VanDuyn, N., Settivari, R., Wong, G., and Nass, R. (2010). SKN-1/Nrf2 inhibits dopamine neuron degeneration in a Caenorhabditis elegans model of methylmercury toxicity. Toxicol. Sci. 118, 613-624. doi: 10.1093/toxsci/kfq285
192. van Ham, T. J., Thijssen, K. L., Breitling, R., Hofstra, R. M., Plasterk, R. H., and Nollen, E. A. (2008). C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS Genet. 4:e1000027. doi: 10.1371/journal.pgen.1000027
193. Ved, R., Saha, S., Westlund, B., Perier, C., Burnam, L., Sluder, A., et al. (2005). Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J. Biol. Chem. 280, 42655-42668. doi: 10.1074/jbc.M505910200
194. Vidal, R., Delisle, M. B., Rascol, O., and Ghetti, B. (2003). Hereditary ferritinopathy. J. Neurol. Sci. 207, 110-111. doi: 10.1016/S0022-510X(02)00435-5
195. Vulpe, C., Levinson, B., Whitney, S., Packman, S., and Gitschier, J. (1993). Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase. Nat. Genet. 3, 6-12. doi: 10.1038/ng0193-7
196. Vymazal, J., Righini, A., Brooks, R. A., Canesi, M., Mariani, C., Leonardi, M., et al. (1999). T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 211, 489-495. doi: 10.1148/radiology.211.2.r99ma53489
197. Waldron, K. J., Rutherford, J. C., Ford, D., and Robinson, N. J. (2009). Metalloproteins and metal sensing. Nature 460, 823-830. doi: 10.1038/nature08300
198. Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., and Kirschner, M. W. (1975). A Protein Factor Essential for Microtubule Assembly. Proc. Natl. Acad. Sci. U.S.A. 72, 1858-1862. doi: 10.1073/pnas.72.5.1858
199. Weinshenker, D., Garriga, G., and Thomas, J. H. (1995). Genetic and pharmacological analysis of neurotransmitters controlling egg laying in C. elegans. J. Neurosci. 15, 6975-6985.
200. Weintraub, D., Doshi, J., Koka, D., Davatzikos, C., Siderowf, A. D., Duda, J. E., et al. (2011). Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch. Neurol. 68, 1562-1568. doi: 10.1001/archneurol.2011.725
201. Wersinger, C., and Sidhu, A. (2003). Attenuation of dopamine transporter activity by α-synuclein. Neurosci. Lett. 340, 189-192. doi: 10.1016/S0304-3940(03)00097-1
202. White, J. G., Southgate, E., Thomson, J. N., and Brenner, S. (1986). The Structure of the nervous system of the nematode Caenorhabditis elegans. Philos. Trans. R. Soc. Lond. B Biol. Sci. 314, 1-340. doi: 10.1098/rstb.1986.0056
203. White, K., and Munro, H. N. (1988). Induction of ferritin subunit synthesis by iron is regulated at both the transcriptional and translational levels. J. Biol. Chem. 263, 8938-8942.
204. Wischik, C. M., Novak, M., Thogersen, H. C., Edwards, P. C., Runswick, M. J., Jakes, R., et al. (1988). Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 85, 4506-4510. doi: 10.1073/pnas.85.12.4506
205. Wooten, G. F. (1997). Functional anatomical and behavioral consequences of dopamine receptor stimulation. Ann. N.Y. Acad. Sci. 835, 153-156. doi: 10.1111/j.1749-6632.1997.tb48626.x
206. Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E. R., and Mizuno, Y. (1996). Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 93, 2696-2701. doi: 10.1073/pnas.93.7.2696
207. Yoshida, K., Furihata, K., Takeda, S., Nakamura, A., Yamamoto, K., Morita, H., et al. (1995). A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat. Genet. 9, 267-272. doi: 10.1038/ng0395-267
208. Youdim, M. B., Ashkenazi, R., Ben-Shachar, D., and Yehuda, S. (1984). Modulation of dopamine receptor in the striatum by iron: behavioral and biochemical correlates. Adv. Neurol. 40, 159-170.
209. Zabetian, C. P., Hutter, C. M., Factor, S. A., Nutt, J. G., Higgins, D. S., Griffith, A., et al. (2007). Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. Ann. Neurol. 62, 137-144. doi: 10.1002/ana.21157
210. Zarranz, J. J., Alegre, J., Gomez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., et al. (2004). The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173. doi: 10.1002/ana.10795